Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy

Research output: Contribution to journalArticlepeer-review


AIM: To assess the sentinel-node identification rate at lymphoscintigraphy and its technical feasibility after neo-adjuvant treatments. MATERIAL OF STUDY: Between 2000 and 2013, 444 consecutive patients affected by primary locally advanced breast cancer were enrolled in this study. All individuals were candidate for neo-adjuvant treatments and for lymphoscintigraphy before surgery. RESULTS: The median age was 44 years at onset; almost one sentinel node was identified during lymphoscintigraphy in 430 cases. The detection rate at lymphoscintigraphy was 96.9% (95% CI, 94.8-98.1%). Considering the correlation between specific treatments and sentinel node identification rate, we verified that the detection rate did not vary significantly (p=0.53) according to the type of neo-adjuvant therapies administered to the patients. CONCLUSIONS: Our results demonstrated that lymphoscintigraphy for sentinel node identification is a safe and feasible procedure after neo-adjuvant therapies, independently of treatment types.

Original languageEnglish
Pages (from-to)201-205
Number of pages5
JournalAnnali Italiani di Chirurgia
Issue number3
Publication statusPublished - May 1 2017


  • Breast Cancer
  • Lymphoscintigraphy
  • Neo-Adjuvant Treatment
  • Sentinel lymphnode biopsy

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy'. Together they form a unique fingerprint.

Cite this